|

Ibrutinib 420 mg Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Gruppo Italiano Malattie EMatologiche dell'Adulto1

Indications

  • Monoclonal B-Cell Lymphocytosis CLL-Type1
  • Autoimmune Hemolytic Anemia1
  • Small Lymphocytic Lymphoma1
  • Chronic Lymphocytic Leukemia1
  • Cancer1

Other1 trial

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.